CXCL12a

CXCL12a, also known as CXCL12a, is a variant of the CXCL12 chemokine, which belongs to the CXC chemokine family. CXCL12 is a key mediator of the chemotactic response to stromal cell-derived factor 1 (SDF-1), a potent chemoattractant for hematopoietic stem cells. CXCL12a is a truncated form of CXCL12 that lacks the first 12 amino acids of the mature protein. This truncation results in a protein that is more stable and resistant to proteolysis, making it a useful tool in research and therapeutic applications.

The CXCL12a variant is particularly important in the context of hematopoietic stem cell (HSC) mobilization, a process used to increase the number of HSCs in the peripheral blood for transplantation. CXCL12a is used as a mobilizing agent to stimulate the release of HSCs from the bone marrow into the bloodstream. This is achieved by binding to CXCR4 receptors on the surface of HSCs, triggering their migration towards the blood vessels.

In addition to its role in HSC mobilization, CXCL12a has been studied for its potential in other therapeutic applications. Its stability and resistance to proteolysis make it a promising candidate for use in vaccines and other therapeutic proteins. However, further research is needed to fully understand its potential and to develop safe and effective therapeutic strategies.

The structure of CXCL12a is similar to that of CXCL12, with the exception of the truncated N-terminus. Both proteins are composed of a single polypeptide chain with a molecular weight of approximately 14 kDa. They share high sequence homology, with CXCL12a exhibiting 92% identity to CXCL12.

In summary, CXCL12a is a truncated variant of the CXCL12 chemokine that plays a crucial role in hematopoietic stem cell mobilization. Its stability and resistance to proteolysis make it a valuable tool in research and therapeutic applications, although further investigation is required to fully realize its potential.